In order to meet its obligations under the Disclosure Rules and Transparency Rules of the United Kingdom Financial Services Authority, Shire plc (“Shire” or the “Group”) (LSE: SHP, NASDAQ: SHPGY) is publishing today its Half Yearly Report for the six months ended June 30, 2010.
It should be noted that on August 4, 2010 Shire previously announced its results in respect of the same period.
For further information please contact:
|Investor Relations||Eric Rojas||+1 781 482 0999|
|Media||Jessica Mann (Rest of the World)||+44 1256 894 280|
|Jessica Cotrone (North America)||+1 781 482 9538|
|Matt Cabrey (North America)||+1 484 595 8248|
Notes to editors
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (“ADHD”), human genetic therapies (“HGT”) and gastrointestinal (“GI”) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire or to view this Half Yearly Report, please visit Shire’s website: www.shire.com